Evidence map›Paper›PMID 37809807›Full record

ArticleHeliyon2023

Characteristics and in-hospital mortality of patients with COVID-19 from the first to fifth waves of the pandemic in 2020 and 2021 in the Japanese Medical Data Vision database.

Toshiki Suzuki, Yuta Taniguchi, Jun Komiyama, Toshiki Kuno, Motohiko Adomi, Toshikazu Abe, Ryota Inokuchi, Atsushi Miyawaki, Shinobu Imai, Makoto Saito and 5 more

Abstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Toshiki SuzukiSchool of Medicine, University of Tsukuba, Tsukuba, Japan.
Yuta TaniguchiGraduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.
Jun KomiyamaGraduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.
Toshiki KunoDepartment of Cardiology, Montefiore Medical Center, Albert Einstein Medical College, NY, USA.
Motohiko AdomiGraduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.
Toshikazu AbeHealth Services Research and Development Center, University of Tsukuba, Tsukuba, Japan.
Ryota InokuchiDepartment of Health Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Atsushi MiyawakiHealth Services Research and Development Center, University of Tsukuba, Tsukuba, Japan.
Shinobu ImaiDivision of Pharmacoepidemiology, Department of Healthcare and Regulatory Sciences, Showa University School of Pharmacy, Tokyo, Japan.
Makoto SaitoDivision of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Hiroyuki OhbeDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Shotaro AsoDepartment of Real World Evidence, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Tadashi KamioDivision of Critical Care, Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan.
Nanako TamiyaHealth Services Research and Development Center, University of Tsukuba, Tsukuba, Japan.
Masao IwagamiHealth Services Research and Development Center, University of Tsukuba, Tsukuba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: We aimed to describe patient characteristics, healthcare utilization, and in-hospital mortality among patients with COVID-19 in Japan across waves. Methods: Using a large-scale hospital-based database, we identified patients hospitalized for COVID-19 in the first (January-June 2020), second (June-October 2020), third (October 2020-February 2021), fourth (March-June 2021), and fifth (June-December 2021) waves. We summarized patient characteristics, healthcare utilization, and in-hospital mortality during each wave and performed multivariable logistic regression analyses for in-hospital mortality. Results: From the first to fifth waves, the number of patients (mean age ± standard deviation, years) was 2958 (61.2 ± 22.8), 7981 (55.6 ± 25.3), 18,788 (63.6 ± 22.9), 17,729 (60.6 ± 22.6), and 23,656 (51.2 ± 22.3), respectively. There were 190 (6.4%), 363 (4.5%), 1261 (6.7%), 1081 (6.1%), and 762 (3.2%) in-hospital deaths, respectively. The adjusted odds ratios for in-hospital deaths (95% confidence interval) were 0.78 (0.65-0.95), 0.94 (0.79-1.12), 0.99 (0.84-1.18), 0.77 (0.65-0.92), in the second to fifth waves, respectively, compared with the first wave. Conclusions: In-hospital COVID-19 mortality improved from the first to the second wave; however, during the third and fourth waves, mortality was as serious as in the first wave. Although in-hospital mortality during the fifth wave improved, careful monitoring is needed for upcoming waves, considering changing patient and viral characteristics.

Indexed as

DexamethasoneElectronic health recordsEpidemiologySevere acute respiratory syndrome coronavirus 2

Identifiers

PMID37809807
PMCPMC10558584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.